Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
N AlShoaibi, M Al Harbi, H Modaimegh, A Al Qubbany, S Al Saif, DL Connolly, S Kharabsheh, M Fathy, Y Hegazy, N Tarcha & A Al Fagih. (2021) Use of NOACS in high-risk patients with atrial fibrillation in Saudi Arabia: Perspectives on improving patient care. Expert Review of Cardiovascular Therapy 19:3, pages 221-236.
Read now
Read now
Articles from other publishers (5)
Chuanlan Sang, Jiming Chen, Junyi Sun, Yuhui Lai, Xiao Liu & Wengen Zhu. (2022)
Off‐label underdosing of four individual
NOACs
in patients with nonvalvular atrial fibrillation: A systematic review and meta‐analysis of observational studies
. European Journal of Clinical Investigation 52:10.
Crossref
Crossref
Alenka Mavri, Nina Vene, Mojca Božič-Mijovski, Marko Miklič, Lisbeth Söderblom, Anton Pohanka, Rickard E. Malmström & Jovan Antovic. (2021) Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation. Scientific Reports 11:1.
Crossref
Crossref
Andreas Brodehl, Hendrik Milting & Brenda Gerull. (2021) Special Issue “Cardiovascular Genetics”. Genes 12:4, pages 479.
Crossref
Crossref
Joana Santos, Natália António, Marília Rocha & Ana Fortuna. (2020) Impact of direct oral anticoagulant off‐label doses on clinical outcomes of atrial fibrillation patients: A systematic review. British Journal of Clinical Pharmacology 86:3, pages 533-547.
Crossref
Crossref
Mariam Ujeyl, Ingrid Köster, Hans Wille, Thomas Stammschulte, Rebecca Hein, Sebastian Harder, Ursula Gundert-Remy, Julian Bleek, Peter Ihle, Helmut Schröder, Gerhard Schillinger, Anette Zawinell & Ingrid Schubert. (2018) Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation. European Journal of Clinical Pharmacology 74:10, pages 1317-1325.
Crossref
Crossref